10.03
전일 마감가:
$9.98
열려 있는:
$10
하루 거래량:
844.93K
Relative Volume:
0.78
시가총액:
$799.92M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.84%
1개월 성능:
+7.67%
6개월 성능:
+0.00%
1년 성능:
+0.00%
Niagen Bioscience Inc Stock (NAGE) Company Profile
명칭
Niagen Bioscience Inc
전화
310-388-6706
주소
10900 WILSHIRE BLVD, LOS ANGELES
NAGE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NAGE
Niagen Bioscience Inc
|
10.03 | 807.10M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-27 | 개시 | Canaccord Genuity | Buy |
2022-08-16 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-08-11 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2022-03-08 | 개시 | ROTH Capital | Buy |
2019-10-16 | 개시 | Oppenheimer | Outperform |
2019-02-14 | 개시 | B. Riley FBR | Buy |
2017-11-27 | 재개 | H.C. Wainwright | Buy |
2017-09-25 | 개시 | Ladenburg Thalmann | Buy |
2017-01-03 | 개시 | Rodman & Renshaw | Buy |
모두보기
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
While Shareholders of Niagen Bioscience (NASDAQ:NAGE) Are in the Black Over 3 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Q3 EPS Forecast for Niagen Bioscience Decreased by Analyst - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Niagen Bioscience's Q2 2025 Earnings: A Catalyst for NAD+ Market Leadership and Long-Term Value Creation - AInvest
Niagen Bioscience, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NAGE) - Seeking Alpha
Quant Models Detect Momentum Reversal in Niagen Bioscience Inc.Stock Surge & Daily Oversold Stock Bounce Ideas - 선데이타임즈
Q2 EPS Estimate for Niagen Bioscience Boosted by Analyst - MarketBeat
Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy - MSN
Is Niagen Bioscience Inc. forming a bullish divergenceWeekly Profit Recap & Proven Capital Preservation Tips - mustnews.co.kr
Is Niagen Bioscience Inc. a defensive stockJuly 2025 Big Picture & Momentum Based Trading Signals - thegnnews.com
RSI Divergence May Trigger a Bounce in Niagen Bioscience Inc.New Guidance & Verified Chart Pattern Signals - newsimpact.co.kr
Is Niagen Bioscience Inc. forming higher highs and higher lowsMarket Activity Summary & AI Powered Market Trend Analysis - thegnnews.com
Bullish Candlestick Pattern Forms in Niagen Bioscience Inc.2025 Year in Review & Free Fast Gain Swing Trade Alerts - metal.it
HC Wainwright Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price - MarketBeat
Niagen Bioscience Inc. Stock Approaches Key Moving Average2025 Earnings Surprises & AI Powered Buy/Sell Recommendations - 선데이타임즈
Q2 EPS Estimate for Niagen Bioscience Increased by Analyst - MarketBeat
Niagen: Imminent Trigger For A Significant Move Up (Technical Analysis) - Seeking Alpha
Quince, Niagen, Intrabio busy in rare A-T disease - BioWorld MedTech
Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience - TipRanks
Equities Analysts Offer Predictions for NAGE Q3 Earnings - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.22 Average PT from Brokerages - MarketBeat
Momentum Screeners Rank Niagen Bioscience Inc. in Top 5 TodayConsistent Income Focused Trade List Analyzed - beatles.ru
Niagen Bioscience stock price target raised to $12 from $11 at H.C. Wainwright - Investing.com Canada
Real time scanner hits for Niagen Bioscience Inc. explainedRisk Balanced Picks for Safer Trading - Newser
Niagen Bioscience Reports Strong Q2 Growth and Outlook - TipRanks
News impact scoring models applied to Niagen Bioscience Inc.In-Depth Stock Trading Volume Analysis - Newser
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Earnings Beat - MarketBeat
Risk adjusted return profile for Niagen Bioscience Inc. analyzedSafe and Scalable Return Strategy Blueprint - Newser
Can Niagen Bioscience Inc. rally from current levelsLow Risk Strategy with Smart Entry Zones - Newser
Roth Capital Cuts Earnings Estimates for Niagen Bioscience - Defense World
Will a bounce in Niagen Bioscience Inc. offer an exitProven Trading System with Consistent Gains - Newser
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Should you wait for a breakout in Niagen Bioscience Inc.Free Fundamental Growth Stock Analysis - Newser
Niagen Bioscience Reports Strong Q2 Sales Growth - The Globe and Mail
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates - MSN
Niagen Bioscience: Q2 Earnings Snapshot - New Haven Register
Niagen Bioscience (NASDAQ:NAGE) Cut to Buy at Wall Street Zen - MarketBeat
Niagen Bioscience shares rise 21.91% premarket after Q2 sales beat estimates. - AInvest
Earnings call transcript: Niagen Bioscience Q2 2025 earnings beat expectations - Investing.com
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook - BioSpace
Niagen NAGE Q2 2025 Earnings Call Transcript - Mitrade
Niagen Bioscience shares rise 24.88% after-hours after Q2 sales beat estimates. - AInvest
Transcript : Niagen Bioscience, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Niagen Bioscience Inc (NAGE) 재무 분석
Niagen Bioscience Inc (NAGE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Niagen Bioscience Inc 주식 (NAGE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
자본화:
|
볼륨(24시간):